Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
02 Sep 2022
Historique:
received: 25 02 2022
accepted: 24 08 2022
entrez: 2 9 2022
pubmed: 3 9 2022
medline: 9 9 2022
Statut: epublish

Résumé

IgA plays an important early neutralizing role after SARS-CoV-2 infection. Systemically administered vaccines typically produce an IgM/IgG predominant response. We evaluated the serum anti-spike (anti-S) IgG, anti-nucleocapsid (anti-N) IgG and anti-S IgA response following vaccination against SARS-CoV-2 in a cohort of first-responders. Among the 378 completely vaccinated participants, 98% were positive for anti-S IgG and 96% were positive for anti-S IgA. Nine percent were positive for anti-N IgG suggesting prior exposure to SARS-CoV-2. No statistically significant difference was seen in IgA response based on prior evidence infection (p = 0.18). Ninety-eight of those receiving the Moderna vaccine (98%) were positive for anti-S IgA as compared to 91% of those who received the Pfizer vaccine (p = 0.0009). The high proportion of participants observed to have a positive anti-S IgA response after vaccination suggests that the vaccines elicit a systemic response characterized by elevated levels of both IgG and IgA.

Identifiants

pubmed: 36056118
doi: 10.1038/s41598-022-19095-7
pii: 10.1038/s41598-022-19095-7
pmc: PMC9437396
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin A 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14932

Informations de copyright

© 2022. The Author(s).

Références

Front Cell Infect Microbiol. 2021 Apr 06;11:655896
pubmed: 33889552
Int J Pharm. 2021 Jun 15;603:120686
pubmed: 33964339
Front Immunol. 2020 May 19;11:902
pubmed: 32508822
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288662
Eur Respir J. 2001 Sep;18(3):571-88
pubmed: 11589357
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33288661
Mucosal Immunol. 2011 Nov;4(6):590-7
pubmed: 21937984
J Infect Dis. 2022 Feb 15;225(4):578-586
pubmed: 34636907
Healthcare (Basel). 2021 Apr 22;9(5):
pubmed: 33922198
Front Immunol. 2021 Oct 12;12:744887
pubmed: 34712232
Scand J Immunol. 2004 Jan;59(1):1-15
pubmed: 14723616
Pathog Immun. 2021 Jun 7;6(1):116-134
pubmed: 34136730
NPJ Vaccines. 2021 May 13;6(1):74
pubmed: 33986272
Hum Vaccin Immunother. 2016 Apr 2;12(4):1070-9
pubmed: 26752023
Curr Opin Infect Dis. 2021 Jun 1;34(3):181-186
pubmed: 33899752

Auteurs

Brian T Montague (BT)

University of Colorado School of Medicine, Aurora, CO, USA. brian.montague@cuanschutz.edu.

Matthew F Wipperman (MF)

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Erica Chio (E)

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Rowena Crow (R)

University of Colorado School of Medicine, Aurora, CO, USA.

Andrea T Hooper (AT)

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Meagan P O'Brien (MP)

Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Eric A F Simões (EAF)

University of Colorado School of Medicine, Aurora, CO, USA. eric.simoes@cuanschutz.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH